The Clinical Efficacy of Topical Nasal Pomegranate Fruit Extract for Patients With Chronic Rhinosinusitis
|ClinicalTrials.gov Identifier: NCT01564849|
Recruitment Status : Unknown
Verified November 2016 by Itzhak Braverman, Hillel Yaffe Medical Center.
Recruitment status was: Recruiting
First Posted : March 28, 2012
Last Update Posted : November 15, 2016
An explosion of interest in the numerous therapeutic properties of Punica granatum over the last decade has led to numerous in vitro, animal, and clinical trials. Pomegranate is a potent antioxidant, superior to red wine and equal to or better than green tea. In addition, anticarcinogenic and anti-inflammatory properties suggest its possible use as a therapy or adjunct for prevention and treatment of several types of cancer and cardiovascular disease. Because of pomegranate's antimicrobial properties, it may aid in preventing infection by dental pathogens, pathogenic E. coli O157:H7, and antibiotic-resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA) Pomegranate's effect on bacterial pathogens has only been tested in vitro, however, necessitating human trials to refute or substantiate any clinical effect.
The possibility that pomegranate extracts may also have an effect on several other disease processes, such as Alzheimer's and obesity, underscores the need for more clinical research. Currently, numerous clinical trials are in progress exploring the therapeutic potential of pomegranate extracts.
Aim The investigators want to evaluate the effect of Punica granatum components on Chronic sinusitis, nasal polyps and chronic rhinitis.
|Condition or disease|
|Rhinitis Sinusitis Nasal Polyps|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||198 participants|
|Observational Model:||Case Control|
|Official Title:||The Clinical Efficacy of Topical Nasal Pomegranate Fruit Extract (PFE) for Patients With Chronic Rhinitis, Chronic Sinusitis With or Without Nasal Polyps|
|Study Start Date :||April 2012|
|Estimated Primary Completion Date :||February 2017|
|Estimated Study Completion Date :||February 2017|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01564849
|Contact: Itzhak Braverman, MDfirstname.lastname@example.org|
|Hillel Yaffe Medical Center||Recruiting|
|Hadera, Pob 169, Israel, 38100|
|Contact: Ahud Sternberg, MD email@example.com|